{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-010014","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2024-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.231285+00:00","generated_at":"2026-06-04T17:33:27.637320+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ensysce reports FY2023 net loss of $10.6M; cash $1.1M; FDA Breakthrough for PF614-MPAR","bullets":["Net loss Q4 2023 $3.5M vs $5.5M; full year $10.6M vs $25.1M (prior year).","Cash $1.1M at Dec 31, 2023; raised $6.8M from warrant exercises in Jan & Feb 2024.","R&D expenses fell to $2.2M (Q4) and $7.6M (FY) from $6.4M and $19.8M.","FDA granted Breakthrough Therapy designation for PF614-MPAR in January 2024.","Phase 3 enrollment for PF614 expected H2 2024 after positive End-of-Phase 2 meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-010014","json":"https://secwatch.observer/filing/0001493152-24-010014.json","markdown":"https://secwatch.observer/filing/0001493152-24-010014.md","text":"https://secwatch.observer/filing/0001493152-24-010014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315224010014/0001493152-24-010014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315224010014/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T17:33:27.637320+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"de3da1f6561ab459535289458a31504300f6b732","claim":"Ensysce Biosciences, Inc. reported financial results for the fourth quarter and full year of 2023.","evidence_excerpt":"On March 15, 2024, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315224010014/0001493152-24-010014-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}